Glucocorticoid-Induced Osteoporosis: New Insights into the Pathophysiology and Treatments

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Purpose of this Review: The goal of the review is to provide an updated understanding of the pathophysiology of glucocorticoid-induced osteoporosis and treatment recommendations. Recent Findings: Glucocorticoids reduce osteoblast and osteocyte lifespan and activity and reduce the vascularity of the bone that together may explain the greater reductions in bone strength than those of bone mass. Treatments with parathyroid hormone fragments appear to reverse glucocorticoid-induced bone loss and fracture risk partially through maintaining bone vascularity and bone strength. Summary: This review identifies how glucocorticoid anti-osteogenic and vascular effects together may reduce bone strength. It also provides guidance to clinicians on rationale treatment for glucocorticoid-induced osteoporosis.

Original languageEnglish (US)
JournalCurrent Osteoporosis Reports
DOIs
StateAccepted/In press - Jan 1 2019

Fingerprint

Glucocorticoids
Osteoporosis
Bone and Bones
Osteocytes
Bone Fractures
Parathyroid Hormone
Osteoblasts
Blood Vessels

Keywords

  • Bone cells
  • Bone vascularity
  • Glucocorticoids
  • Osteonecrosis
  • Parathyroid hormone

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism

Cite this

@article{ff3b0a78e35a4fcba78809a9acbfa2fe,
title = "Glucocorticoid-Induced Osteoporosis: New Insights into the Pathophysiology and Treatments",
abstract = "Purpose of this Review: The goal of the review is to provide an updated understanding of the pathophysiology of glucocorticoid-induced osteoporosis and treatment recommendations. Recent Findings: Glucocorticoids reduce osteoblast and osteocyte lifespan and activity and reduce the vascularity of the bone that together may explain the greater reductions in bone strength than those of bone mass. Treatments with parathyroid hormone fragments appear to reverse glucocorticoid-induced bone loss and fracture risk partially through maintaining bone vascularity and bone strength. Summary: This review identifies how glucocorticoid anti-osteogenic and vascular effects together may reduce bone strength. It also provides guidance to clinicians on rationale treatment for glucocorticoid-induced osteoporosis.",
keywords = "Bone cells, Bone vascularity, Glucocorticoids, Osteonecrosis, Parathyroid hormone",
author = "Lane, {Nancy E}",
year = "2019",
month = "1",
day = "1",
doi = "10.1007/s11914-019-00498-x",
language = "English (US)",
journal = "Foodborne Pathogens and Disease",
issn = "1744-165X",
publisher = "W.B. Saunders Ltd",

}

TY - JOUR

T1 - Glucocorticoid-Induced Osteoporosis

T2 - New Insights into the Pathophysiology and Treatments

AU - Lane, Nancy E

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Purpose of this Review: The goal of the review is to provide an updated understanding of the pathophysiology of glucocorticoid-induced osteoporosis and treatment recommendations. Recent Findings: Glucocorticoids reduce osteoblast and osteocyte lifespan and activity and reduce the vascularity of the bone that together may explain the greater reductions in bone strength than those of bone mass. Treatments with parathyroid hormone fragments appear to reverse glucocorticoid-induced bone loss and fracture risk partially through maintaining bone vascularity and bone strength. Summary: This review identifies how glucocorticoid anti-osteogenic and vascular effects together may reduce bone strength. It also provides guidance to clinicians on rationale treatment for glucocorticoid-induced osteoporosis.

AB - Purpose of this Review: The goal of the review is to provide an updated understanding of the pathophysiology of glucocorticoid-induced osteoporosis and treatment recommendations. Recent Findings: Glucocorticoids reduce osteoblast and osteocyte lifespan and activity and reduce the vascularity of the bone that together may explain the greater reductions in bone strength than those of bone mass. Treatments with parathyroid hormone fragments appear to reverse glucocorticoid-induced bone loss and fracture risk partially through maintaining bone vascularity and bone strength. Summary: This review identifies how glucocorticoid anti-osteogenic and vascular effects together may reduce bone strength. It also provides guidance to clinicians on rationale treatment for glucocorticoid-induced osteoporosis.

KW - Bone cells

KW - Bone vascularity

KW - Glucocorticoids

KW - Osteonecrosis

KW - Parathyroid hormone

UR - http://www.scopus.com/inward/record.url?scp=85060697239&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060697239&partnerID=8YFLogxK

U2 - 10.1007/s11914-019-00498-x

DO - 10.1007/s11914-019-00498-x

M3 - Article

C2 - 30685820

AN - SCOPUS:85060697239

JO - Foodborne Pathogens and Disease

JF - Foodborne Pathogens and Disease

SN - 1744-165X

ER -